Feature | June 09, 2014

Stem Cell Stimulating Therapy Saves Heart Attack Patients

SPECT study shows how early administration of the treatment aids survival of those recovering from myocardial infarction

June 9, 2014 — Researchers at the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting (SNMMI) revealed how a protein encourages the production of stem cells that regenerate damaged tissues of the heart following an acute attack (myocardial infarction). They further assert that it has a better chance of working if provided early in treatment. This was confirmed by molecular imaging, which captured patients’ improved heart health after therapy. 

If given after a heart attack, granulocyte colony-stimulating factor (G-CSF) mobilizes bone marrow stem cells that turn down the collateral damage of cell death that occurs after acute myocardial infarction. Other research has shown G-CSF having a beneficial impact on left ventricle ejection fraction, a measurement of how powerfully the heart is pumping oxygenated blood back into the aorta and the rest of the body with each beat. The objective of this study was to find out how beneficial the stem cell–stimulating therapy would be if administered early during standard treatment. Early prescription of G-CSF happens to strengthen its effect immediately and after follow up.

“Previous studies have shown that giving G-CSF to unselected heart attack patients failed to satisfactorily improve their condition, but G-CSF may potentially be beneficial if given earlier than 37 hours following myocardial infarction and coronary intervention,” said Takuji Toyama, M.D., the study’s principal researcher from the division of cardiology at Gunma Prefectural Cardiovascular Center in Maebashi, Japan. “This study shows that the first intravenous drip infusion of G-CSF during treatment just after hospitalization was able to rescue our patients. I am confident that with additional data from a forthcoming clinical trial, this protocol can be adopted as a standard of practice.”

For this study, 40 consecutive patients with acute myocardial infarction were given either G-CSF therapy or saline intravenously for a total of five days beginning during a selected minimally invasive treatment, otherwise known as percutaneous cardiac intervention. Results of one year’s worth of single photo emission computed tomography (SPECT) stress tests nailed how earlier start of G-CSF therapy in heart attack patients improves blood flow, access to essential energy and overall cardiac function. 

Coronary heart disease caused one out of every six fatalities in the U.S. in 2010, according to 2014 statistics from the American Heart Association. An estimated 620,000 Americans suffered a first heart attack, and 295,000 had a recurrent episode. Collectively, heart attacks occur about once every 34 seconds. Coronary events cause about 379,559 deaths each year.

For more information: www.snmmi.org.

 

 

Related Content

UltraSPECT, 10th anniversary, WBR technology, Wide Beam Reconstruction, FDA approval, nuclear imaging
News | Nuclear Imaging| April 21, 2016
UltraSPECT Inc. announced the 10th anniversary of the U.S. Food and Drug Administration (FDA) approval of its Wide Beam...
News | Heart Failure| April 15, 2016
April 15, 2016 — An investigational stem cell therapy derived from patients’ own blood marrow significantly improved
ixCELL-DCM trial, stem cell therapy, heart failure, ACC 2016, Amit Patel

Three-dimensional electrochemical mapping was used to target ixmyelocel-T cell therapy to damaged areas of hearts in patients with end-stage heart failure. Image courtesy of Matthew Brobeck.

News | Stem Cell Therapies| April 06, 2016
End-stage heart failure patients treated with stem cells harvested from their own bone marrow experienced 37 percent...
PET/CT scan, brain stress center, heart disease predictor, ACC.16
News | PET-CT| April 05, 2016
New research shows individuals with a greater degree of activity in the stress center of the brain also have more...
cardiac stem cells, heart failure with preserved ejection fraction, Cedars-Sinai Heart Institute study
News | Stem Cell Therapies| March 01, 2016
Cardiac stem cells could be an effective treatment for a common but difficult-to-treat type of heart failure, a new...
cardiac progenitor cells, UW-Madison study, mouse fibroblasts

Induced cardiac progenitor cells (iCPCs) injected into hearts of mice with experimentally induced heart attacks generate new heart muscle. Newly developed heart muscle cells are shown by overlapping red (heart muscle protein) and green (iCPC protein) labeling, and cell nuclei are shown in blue. Image courtesy of Pratik Lalit.

News | Stem Cell Therapies| February 16, 2016
By genetically reprogramming the most common type of cell in mammalian connective tissue, researchers at the University...
cardiomyocytes, electrical stimulation, human stem cells, Columbia Engineering

Electrically conditioned human cardiomyocytes. Striated ultrastructure containing troponin ( stained in green) forms around cell nuclei (stained in blue.) Image courtesy of Benjamin Lee, Columbia Engineering

News | Stem Cell Therapies| February 09, 2016
Columbia Engineering researchers have shown, for the first time, that electrical stimulation of human heart muscle...
UltraSPECT, 450th U.S. installation, Firelands Regional Medical Center, nuclear medicine, radiation safety
News | Nuclear Imaging| January 27, 2016
UltraSPECT Inc. has marked the 450th U.S. installation of its low-dose image processing technology for nuclear medicine...
Siemens, Biograph Horizon PET CT, FDA clearance
Technology | PET-CT| January 21, 2016
Siemens Healthcare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Biograph...
News | Stem Cell Therapies| January 07, 2016
January 7, 2016 — Celyad announced Dec. 21 that the U.S.
Overlay Init